Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
P/E ratio for Tyra Biosciences, Inc. (TYRA)
P/E ratio as of 2023: -8.56
According to Tyra Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.56. At the end of 2022 the company had a P/E ratio of -6.15.
P/E ratio history for Tyra Biosciences, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -8.56 |
| 2022 | -6.15 |
| 2021 | -22.31 |
| 2020 | -118.74 |
| 2019 | -272.53 |